Captures sustained directional moves using momentum indicators
| Strategy Type | Trend-Following Momentum Trading |
| Market Outlook | Captures sustained directional moves using momentum indicators |
| Risk Profile | Moderate - Defensive blue-chip stability with single-stock and pharma-pipeline concentration |
| Reward Profile | 1:2 to 1:4 risk-reward on trending moves; 5-15% swing profits typical |
| Time Horizon | Swing trading (5-20 days) to Positional (1-3 months) |
| Capital Requirement | GBP 3,000 - GBP 15,000 for meaningful cash exposure; less upfront via CFD/spread-bet margin |
| Margin Type | Cash for delivery (GIA or ISA); margin for CFDs/spread bets |
| Best Used When | AstraZeneca showing a clear trend with momentum confirmation and pharma sector strength |
| Lse Applicability | AstraZeneca is one of the largest companies on the London Stock Exchange (market cap ~GBP 200bn) and a global pharmaceutical leader; deep liquidity (~12m+ shares/day) and heavy institutional ownership produce clean, trend-friendly moves; as the dominant constituent of the FTSE 350 Pharmaceuticals & Biotechnology index it frequently leads UK pharma sector direction. As a predominantly US-dollar earner it is a classic FTSE 100 'dollar stock' that benefits when sterling weakens. The share is quoted in pence (GBX) on the LSE. |
| Fca Compliance | Standard momentum strategy fully compatible with FCA conduct rules and the UK market abuse regime (UK MAR); uses only exchange-listed instruments and FCA-regulated leverage products. CFDs and spread bets carry mandatory FCA risk warnings. |
| Lot Sizes | 1 CFD = 1 share; leverage via margin (retail margin typically 20%, i.e. 5:1, under FCA leverage limits) • Listed equity options (ICE/Euronext): 100 shares per contract - but UK single-stock option retail liquidity is thin and spreads can be wide • No lot restriction; position sized by capital. 0.5% Stamp Duty Reserve Tax on purchases; settles T+2 (UK moving to T+1 in October 2027) |
| Trading Hours | 8:00 AM - 4:30 PM London time (GMT/BST); opening auction 07:50-08:00, closing auction 16:30-16:35. Pre-open guidance from the overnight US pharma close and US index futures given AstraZeneca's heavy US exposure |
| Expiry Considerations | Listed options expire the third Friday monthly; roll 5-7 days before expiry for positional option trades. CFDs and spread bets have no expiry but incur daily overnight financing, so suit shorter holds; dated/quarterly spread bets avoid daily financing |
| Tax Implications | Cash shares in a General Investment Account: Capital Gains Tax 18% (basic-rate band) / 24% (higher or additional rate) on gains above the GBP 3,000 annual exempt amount; 0.5% stamp duty on purchases; dividends taxed 8.75%/33.75%/39.35% above the GBP 500 allowance. Inside a Stocks & Shares ISA (GBP 20,000 annual allowance) all gains and dividends are tax-free. Spread-bet profits are free of CGT and stamp duty; CFD profits are subject to CGT but exempt from stamp duty. Tax depends on individual circumstances and can change |
AZN offers cleaner trends due to institutional ownership, the highest liquidity for easy entry/exit, and lower volatility than small/mid-cap biotech while still providing tradeable swings. It is the UK pharma bellwether, often leading sector moves.
AstraZeneca earns mostly in foreign currency (predominantly USD) and reports in USD. When the pound weakens (GBP/USD falls), the sterling value of those earnings rises, supporting the pence price. Monitor GBP/USD as a tailwind/headwind indicator.
For cash shares with proper position sizing: GBP 3,000-5,000 minimum (using an ISA shelters gains tax-free). CFDs/spread bets need less upfront margin but carry higher risk - most retail accounts lose money on them. Start with cash for learning.
Generally reduce the position by ~50% before results due to gap risk, and be aware of pipeline/FDA dates too. Post-results, reassess based on numbers and guidance. Strong results can create momentum opportunities.
Quality momentum signals occur roughly 4-8 times per year. Don't force trades - wait for proper alignment of indicators, trend and volume.
Check the FTSE Pharma trend first. AZN momentum + pharma sector strength = higher probability. AZN momentum against a weak sector = lower probability. The sector provides context for individual stock trades.
A pullback to the 20 EMA offers the best risk-reward. Wait for the momentum signal, then enter on the pullback with a defined stop. Scale: 60% on the pullback, 40% on confirmation.
No new entries 7 days before results; reduce existing positions ~50%. Avoid being fully sized into known Phase III readouts or FDA/EMA decision dates. Post-results: wait 30-60 minutes to assess the gap, enter only if it holds with volume.
Use shares (ideally in an ISA) for longer holds, dividends and tax-free gains. Use CFDs or spread bets for leverage and around events (spread bets are CGT/stamp-duty free; CFDs are CGT-liable). UK single-stock options give defined risk but have thin liquidity.
Initial: below the 20 EMA. After +5%: move to breakeven. After +8%: trail at the 20 EMA. After +12%: consider a 2x ATR trail for larger gains.
Use 5+ years of data with a 70/30 in-sample/out-of-sample split. Test ROC periods 10-16, RSI zones 50-80, and EMA combinations. Accept <20% out-of-sample degradation. Standard parameters are often near-optimal.
Target: 50-55% win rate, 2.5-3.0x win/loss ratio, Sharpe >1.2. It should outperform AZN buy-and-hold with lower drawdown. Expect 4-8 trades per year.
AZN-GSK correlation is ~0.6. If long AZN momentum, avoid a simultaneous long GSK. Keep total healthcare exposure <30% of the portfolio. Consider hedging if overweight.
Where liquid: ITM calls (delta 0.70+) for directional plays and bull call spreads for defined risk. More commonly in the UK: CFDs or spread bets for liquid leverage - match the instrument to conviction, tax position and the binary-event calendar.
Decompose returns into market beta, sector contribution, stock selection and timing. Compare to AZN buy-hold and the FTSE 350 Pharma index. Journal trades for pattern identification.
Full guided lessons, quizzes, and a complete strategy library for the United Kingdom market. One-time purchase. No subscription, ever.
Get United Kingdom access →